GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Open Access
- 30 December 2025
- journal article
- Published by Quality Academic And Scientific Publishing Agency (QAASPA Publisher) in BioMed Target Journal
- Vol. 3 (2) , 18-28
Abstract
Worldwide prevalence of type 2 diabetes mellitus (T2DM) and obesity has heightened the need to find treatments that control hyperglycemia, together with weight gain and resultant organ damage. Under this arrangement, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents. They act through both intra- and extrapancreatic pathways to promote glucose-dependent insulin secretion, lower glucagon concentrations, slow stomach emptying, and control circuits of cerebral appetite. This helps the body regulate blood glucose levels, leading to clinically significant weight loss. In addition to regulating metabolism, strong cardiovascular and renal outcome trial data (including STEP, SELECT, and FLOW) suggest that they can lower the disease burden of serious cardiovascular events and protect kidney functioning. It means they are disease-modifying agents. Other barriers include their high cost, gastrointestinal side effects, injectable formulations, and lack of long-term safety information, although they are an effective intervention for achieving greater use. Recently, novel agents such as oral semaglutide, dual and triple incretin agonists (tirzepatide, retatrutide), and drug-based combinations with sodium-glucose cotransporter-2 (SGLT2) have revolutionized the treatment of the disease and improved its clinical utility. Individualized optimization of treatment using precision medicine, in the form of tailored behavior, with respect to phenotypes and comorbidities, holds promise to enhance outcomes. The combination of glycemic control, long-term weight loss, and organ protection is shifting the approach to cardiac, renal, and other organ health, leveraging the action of GLP-1 receptor agonists.Keywords
This publication has 39 references indexed in Scilit:
- Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapiesDiabetes, Obesity and Metabolism, 2025
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapySignal Transduction and Targeted Therapy, 2024
- Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapyInternational Journal of Obesity, 2024
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2024
- A Revolution in the Treatment of ObesityThe American Journal of Medicine, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialNew England Journal of Medicine, 2023
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Glucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone FunctionComprehensive Physiology, 2020